Abstract 1768
Background
Taste changes can frequently be observed in oncological patients undergoing chemotherapy and are reported as being among the most distressing side effects, along with fatigue, nausea, vomiting, and hair loss. The prevalence of taste changes have been reported in the range of 46%–77%. The aim of this descriptive study was to evaluate taste changes experienced by cancer patients who receive chemotherapy and associated factors with taste changes.
Methods
This is a descriptive a study. The sample of the study consisted of 154 patients who received chemotherapy at Gayrettepe Florence Nightingale Hospital during the period of February 2018 to July 2018. Data were collected by using the patient İnformation form and Chemotherapy-induced Taste Alteration Scale (CiTAS). Mann-Whitney U test, Kruskal-Wallis test, and Spearman Correlation analysis were used to evaluate the data.
Results
The mean age of patients was 57,40±12,748 years, 62.3% of them were women, 43.5% of them were university graduates, 73.4% were married and 70.8% of them were employed in any job. According to CiTAS scores, the most discomfort in taste patients experienced was because of nausea, vomiting, odor disturbance and loss of appetite during the chemotherapy process. According to CiTAS score the least discomfort experienced by patients were tasting basic flavors including the taste of the sweet, salty, bitter flavors and the broth. As a result of the comparison of CiTAS score some sociodemographic and medical characteristics of patients, it was found that women experience more paraguzi and fantoguzi than men. As the age of the patients increased, the problems in taste were decreased. Patients who do not take other drugs than chemotherapy have fewer taste problems.
Conclusions
In conclusion, it is recommended to include changes in taste sensation along with other side effects in the evaluation of treatment-related processes of cancer patients, and to add practices related to management of taste changes in the care plan of the patients by taking into account the factors that may be associated with taste.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4543 - Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Presenter: Stéphane Dalle
Session: Poster Display session 3
Resources:
Abstract
4523 - Prognostic Factors for efficacy of Ipilimumab used after AntiPD1 and/or BRAF+MEK inhibitors in Melanoma Patients: an Italian Melanoma Intergroup study
Presenter: Riccardo Marconcini
Session: Poster Display session 3
Resources:
Abstract
3632 - Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Presenter: Adriana Hepner
Session: Poster Display session 3
Resources:
Abstract
3732 - Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy.
Presenter: Kazi Nahar
Session: Poster Display session 3
Resources:
Abstract
5005 - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Presenter: Michiel van Zeijl
Session: Poster Display session 3
Resources:
Abstract
5524 - Utilization of Real-World Data to Assess the Effectiveness of Immune Checkpoint Inhibitors (ICIs) in Elderly Patients with Metastatic Melanoma
Presenter: D Scott Ernst
Session: Poster Display session 3
Resources:
Abstract
5884 - Tumor mutational burden and response to PD-1 inhibitors: an analysis of 89 cases of metastatic melanoma.
Presenter: Léa Dousset
Session: Poster Display session 3
Resources:
Abstract
3120 - Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.
Presenter: Elisa Rozeman
Session: Poster Display session 3
Resources:
Abstract
2157 - Immune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma
Presenter: Guillermo Prado-Vázquez
Session: Poster Display session 3
Resources:
Abstract
2553 - Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
Presenter: Shahneen Sandhu
Session: Poster Display session 3
Resources:
Abstract